propranolol has been researched along with Soft Tissue Neoplasms in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe." | 7.88 | Safety of Oral Propranolol for Infantile Hemangioma. ( Botrel, MA; Droitcourt, C; Dupuy, A; Garlantezec, R; Guillot, B; Happe, A; Kerbrat, S; Oger, E; Rault, C; Schleich, JM, 2018) |
| "Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile." | 7.79 | Propranolol for hemangiomas. ( Hasan, M; Hoque, S; Khondker, L; Rahman, M; Zahid Hossain, AK, 2013) |
| "Standard chemotherapy for soft tissue sarcomas has shown limited efficacy." | 5.56 | The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. ( Azzariti, A; Di Fonte, R; Fucci, L; Garofoli, M; Guida, M; Porcelli, L; Strippoli, S; Volpicella, M, 2020) |
| "The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe." | 3.88 | Safety of Oral Propranolol for Infantile Hemangioma. ( Botrel, MA; Droitcourt, C; Dupuy, A; Garlantezec, R; Guillot, B; Happe, A; Kerbrat, S; Oger, E; Rault, C; Schleich, JM, 2018) |
| "Intralesional compound betamethasone preparation is a feasible choice for the small-size hemangioma." | 3.81 | Intralesional injection of diprospan is effective for infantile hemangioma. ( Cui, L; Guo, Y; Hong, ZJ; Jiang, HQ; Yuan, SM; Zhang, M, 2015) |
| "Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile." | 3.79 | Propranolol for hemangiomas. ( Hasan, M; Hoque, S; Khondker, L; Rahman, M; Zahid Hossain, AK, 2013) |
| "Standard chemotherapy for soft tissue sarcomas has shown limited efficacy." | 1.56 | The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. ( Azzariti, A; Di Fonte, R; Fucci, L; Garofoli, M; Guida, M; Porcelli, L; Strippoli, S; Volpicella, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, K | 1 |
| Ozeki, M | 1 |
| Yasue, S | 1 |
| Endo, S | 1 |
| Fukao, T | 1 |
| Porcelli, L | 1 |
| Garofoli, M | 1 |
| Di Fonte, R | 1 |
| Fucci, L | 1 |
| Volpicella, M | 1 |
| Strippoli, S | 1 |
| Guida, M | 1 |
| Azzariti, A | 1 |
| Droitcourt, C | 1 |
| Kerbrat, S | 1 |
| Rault, C | 1 |
| Botrel, MA | 1 |
| Happe, A | 1 |
| Garlantezec, R | 1 |
| Guillot, B | 1 |
| Schleich, JM | 1 |
| Oger, E | 1 |
| Dupuy, A | 1 |
| Yuan, SM | 1 |
| Zhang, M | 1 |
| Guo, Y | 1 |
| Cui, L | 1 |
| Hong, ZJ | 1 |
| Jiang, HQ | 1 |
| Freshwater, MF | 1 |
| Hasan, M | 1 |
| Rahman, M | 1 |
| Hoque, S | 1 |
| Zahid Hossain, AK | 1 |
| Khondker, L | 1 |
6 other studies available for propranolol and Soft Tissue Neoplasms
| Article | Year |
|---|---|
A retrospective study of 2 or 3 mg/kg/day propranolol for infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propran | 2020 |
The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study.
Topics: Adrenergic beta-Antagonists; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Drug Resistance, Neopl | 2020 |
Safety of Oral Propranolol for Infantile Hemangioma.
Topics: Administration, Oral; Bradycardia; Bronchitis; Child, Preschool; Cohort Studies; Databases, Factual; | 2018 |
Intralesional injection of diprospan is effective for infantile hemangioma.
Topics: Betamethasone; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Head and Neck Neoplasm | 2015 |
Treatment of vascular anomalies of the upper extremity.
Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Male; Propranolol; Radiography; Risk Assessment | 2011 |
Propranolol for hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Response Relationsh | 2013 |